Company profile for BioAxone BioSciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

BioAxone is a clinical-stage biopharmaceutical company that is transforming treatments for neurotrauma and neurovascular disorders. The company has developed innovative therapies based on a deep understanding of axon regeneration and neuronal signaling pathways. BioAxone has an IND-ready ROCK-2 selective, oral kinase inhibitor, BA-1049, for treatment of neurovascular disorders. ROCK2 signaling is overactivated in endothelial ...
BioAxone is a clinical-stage biopharmaceutical company that is transforming treatments for neurotrauma and neurovascular disorders. The company has developed innovative therapies based on a deep understanding of axon regeneration and neuronal signaling pathways. BioAxone has an IND-ready ROCK-2 selective, oral kinase inhibitor, BA-1049, for treatment of neurovascular disorders. ROCK2 signaling is overactivated in endothelial cells in hereditary angioma, a disease where benign vascular malformations are “leaky” and can cause stroke. Similarly, in acute ischemic stroke, ROCK2 is hyperactivated in brain vascular endothelial cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
90 Canal Street, 4th Floor Boston, Massachusetts 02114
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

DCAT Week

DCAT Week

Not Confirmed

envelop Contact Supplier

DCAT Week

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20220622005280/en

BUSINESSWIRE
22 Jun 2022

https://www.businesswire.com/news/home/20210608005831/en/BioAxone-BioSciences-Announces-Notice-of-Allowance-for-Self-Delivering-RNA-Interference-for-the-Treatment-of-Spinal-Cord-Injury

BUSINESSWIRE
08 Jun 2021

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty